Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015;Hypertonie oculaire après injections intra-vitréennes de corticoïdes, actualisation des connaissances en 2015

Journal Francais d'Ophtalmologie

Volumn 38, Issue 7, 2015, Pages 656-664

  Dot, C ^a   El Chehab, H ^a   Russo, A ^a   Agard, E ^a  

^a HIA Desgenettes   (France)

Author keywords

Intravitreal injection; Ocular hypertension; Steroids

Indexed keywords

ACETAZOLAMIDE; CORTICOSTEROID; DELAYED RELEASE FORMULATION; DEXAMETHASONE; DRUG IMPLANT; EYE DROPS; FLUOCINOLONE ACETONIDE; OINTMENT; TRIAMCINOLONE ACETONIDE;

ADULT; ANIMAL; CHEMICALLY INDUCED; CHILD; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG IMPLANT; FILTERING OPERATION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; OCULAR HYPERTENSION; OINTMENT; RABBIT; RETINAL DISEASES; RISK FACTOR;

ACETAZOLAMIDE; ADRENAL CORTEX HORMONES; ADULT; ANIMALS; CHILD; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FILTERING SURGERY; FLUOCINOLONE ACETONIDE; HUMANS; INTRAVITREAL INJECTIONS; OCULAR HYPERTENSION; OINTMENTS; OPHTHALMIC SOLUTIONS; RABBITS; RETINAL DISEASES; RISK FACTORS; TRIAMCINOLONE ACETONIDE;

EID: 84941598790     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2015.03.002     Document Type: Review

References (32)

1. P.L. Penfold, J.F. Gyory, A.B. Hunyor, and F.A. Billson Exudative macular degeneration and intravitreal triamcinolone. A pilot study Aust N Z J Ophthalmol 23 1995 293 298
2. W.1. Kiddee, G.E. Trope, L. Sheng, L. Beltran-Agullo, M. Smith, M.H. Strungaru, and et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review Surv Ophthalmol 58 2013 291 310
3. K.M. Sampat, and S.J. Garg Complications of intravitreal injections Curr Opin Ophthalmol 21 2010 178 183
4. J. François Cortisone et tension oculaire Ann Ocul (Paris) 187 1954 805 816
5. M.F. Armaly Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of the dexamethasone in the normal eye Arch Ophthalmol 70 1963 482 491
6. M.F. Armaly Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of the dexamethasone on the glaucomatous eye Arch Ophthalmol 70 1963 492 499
7. B. Becker, and D.W. Mills Corticosteroids and intraocular pressure Arch Ophthalmol 70 1963 500 507
8. Razeghinejad MR1, and L.J. Katz Steroid-induced iatrogenic glaucoma Ophthalmic Res 47 2012 66 80
9. T. Kubota, H. Okabe, T. Hisatomi, K. Yamakiri, T. Sakamoto, and A. Tawara Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide J Glaucoma 15 2006 117 119
10. D. Johnson, J. Gottanka, C. Flugel, F. Hoffmann, R. Futa, and E. Lütjen-Drecoll Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids Arch Ophthalmol 115 1997 375 383
11. D. Chun, A. Shapiro, and M. Abelson Ocular pharmacokinetics Albert & Jakobiec's principles & practice in ophthalmology 3rd ed. 2008 Saunders Elsevier edition Philadelphia 179 192
12. T.U. Krohne, P.S. Muether, N.K. Stratmann, F.G. Holz, B. Kirchhof, C.H. Meyer, and et al. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors Retina 35 2015 69 74
13. S. Bakri, M. Snyder, J. Reid, J. Pulido, M. Ezzat, and R. Singh Pharmacokinetics of Intravitreal Ranibizumab (Lucentis) Ophthalmology 114 2007 2179 2182
14. S. Peters, P. Heiduschka, S. Julien, K.U. Bartz-Schmidt, and U. Schraermeyer Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye Br J Ophthalmol 92 2008 541 544
15. P.A. Campochiaro, Q.D. Nguyen, G. Hafiz, S. Bloom, D.M. Brown, M. Busquets, and et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinoloneacetonide implants Ophthalmology 120 2013 583 587
16. K.E. Bollinger, and S.D. Smith Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant Curr Opin Ophthalmol 20 2009 99 103
17. P.A. Campochiaro, D.M. Braown, A. Pearson, and et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema Ophthalmology 119 2012 2125 2132
18. D.S. Boyer, Y.H. Yoon, R. Belfort Jr., F. Bandello, R.K. Maturi, A.J. Augustin, and et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 121 2014 1904 1914
19. The SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6 Arch Ophthalmol 127 2009 1115 1128
20. J.A. Haller, F. Bandello, R. Belfort Jr., M.S. Blumenkranz, M. Gillies, J. Heier, and et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results Ophthalmology 118 2011 2453 2460
21. J.B. Jonas Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases Acta Ophthalmol Scand 83 2005 645 663
22. A.J. Lotery Long-term therapies for diabetic macular edema Eur Ophthal Rev 6 2012 236 241
23. J.E. Chang-Lin, M. Attar, A.A. Acheampong, M.R. Robinson, S.M. Whitcup, B.D. Kuppermann, and et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant Invest Ophthalmol Vis Sci 52 2011 80 86
24. D.J. Rhee, R.E. Peck, J. Belmont, A. Martidis, M. Liu, J. Chang, and et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide Br J Ophthalmol 90 2006 999 1003
25. M. Inatani 1., K. Iwao, T. Kawaji, Y. Hirano, Y. Ogura, K. Hirooka, and et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study Am J Ophthalmol 145 2008 676 681
26. C. Breuseguem, E. Vandewalle, J. Van Caster, I. Stalmans, and T. Zegen Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection Investig Ophtalmol Vis Sci 50 2009 573 576
27. D.V. Vasconcelos-Santos, P.G. Nehemy, A.P. Schachat, and M.B. Nehemy Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors Retina 28 2008 573 580
28. F. Matonti, F. Meyer, S. Guigou, T. Barthelemy, S. Dumas, F. Gobert, and et al. Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice Acta Ophthalmol 91 2013 e584 e586
29. S. Pommier, and F. Meyer Résultats d'une étude multicentrique de l'implant de dexaméthasone dans l'œdème maculaire des oblitérations veineuses rétiniennes: étude RE.MI.DO Real Ophtalmol 195 2012 1 4
30. D.S. Lam, D.S. Fan, J.S. Ng, C.B. Yu, C.Y. Wong, and A.Y. Cheung Ocular hypertensive and antiinflammatory responses to different dosages of topical dexamethasone in children: a randomized trial Clin Experiment Ophthalmol 33 2005 252 258
31. Caillaux V1, F. Valtot, E.H. Souied, and G. Mimoun Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion Eur J Ophthalmol 2015 10.5301/ejo.5000585 [Epub ahead of print]
32. A.L. Vie, L. Kodjikian, A. Malcles, E. Agard, El ChehabH, and C. Dot Dexamethasone intravitreal implant tolerance in OHT and OAG patients, about 30 cases 2015 [Poster présenté au congrès de l'ARVO, Denver (Colorado)]